Search

High unmet medical need for therapies that can reduce the substantial treatment burden affecting millions of patients globally Combined in-licensing and financing for a novel long-acting clinical stage monoclonal antibody [...]

ROYAL OAK, Mich., Jan. 7, 2025 /PRNewswire/ -- Parallel ENT & Allergy has added https://c212.net/c/link/?t=0&l=en&o=4330682-1&h=885763712&u=https%3A%2F%2Fwww.allergyctr.com%2F&a=Allergy+%26+Asthma+Associates+of+Michigan as a Parallel supported practice. Parallel will provide non-clinical, practice management services to provide the [...]

Independent Data Monitoring Committee recommended trial stop early due to overwhelming efficacy at pre-planned analysis AstraZeneca's inhaled anti-inflammatory rescue medication AIRSUPRA demonstrated significant benefit compared to albuterol WILMINGTON, Del. -- [...]

M2 PRESSWIRE-May 21, 2024-: GSK announces positive results from phase III severe asthma trials of depemokimab | GSK (C)1994-2024 M2 COMMUNICATIONS RDATE:21052024 * Primary endpoints met in SWIFT-1 and SWIFT-2 [...]

- Funding secured from CF Foundation and current investors for SPL84 Phase 2 study - - Two additional early-stage candidates expected to commence Phase 1-2a studies over the next 12 [...]

Byline: PHARMACEUTICALS Simon Hunt THE first major takeover of 2024 sparked life into London's M&A market today when pharma g iant GSK unveiled plans to buy asthma drug maker Aiolos [...]

Byline: Gali Weinreb Dec. 14Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) and Israeli company Biolojic Design have signed a collaboration agreement. Teva will complete development of Biolojic's antibody-based therapy [...]

WASHINGTON, Feb. 25, 2024 /PRNewswire/ -- Longbio Pharma (Suzhou) Co., Ltd. (referred to as 'Longbio Pharma'), a leading biotech company dedicated to developing innovative protein treatments for allergy, respiratory, dermatology, [...]

FASENRA enabled patients to taper off oral corticosteroids while preventing relapses WILMINGTON, Del. -- Positive results from the MANDARA Phase III trial for FASENRA([R]) (benralizumab) in patients with EGPA were [...]

Phase 1 clinical trial will enroll 88 healthy volunteers in the United Kingdom ETH47 is a first-in-class, broadly protective antiviral candidate developed using Ethris' proprietary platform technologies for the treatment [...]

SAN DIEGO, CA and TAICANG, China, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) ('Connect Biopharma' or the 'Company'), a global clinical-stage biopharmaceutical company dedicated to [...]

New datasets deliver insights into treatment effectiveness, patient subtypes, and patient outcomes for accelerating research and improving decision making BOSTON -- OM1, a leading real-world data, AI, and technology company [...]

GSK plc and Aiolos Bio reported they have entered into an agreement under which GSK will acquire Aiolos, a clinical-stage biopharmaceutical company focused on addressing the unmet treatment needs of [...]

AVTX-002 did not meet the primary endpoint measured by reduction in asthma related events compared to placebo, although positive trends were observed among a sub-population of patients with elevated baseline [...]

OM1, an AI and technology company with a focus on chronic diseases, recently reported the launch of two new clinical datasets, Chronic Rhinosinusitis (CRS) and Asthma. The company said that [...]

- Interim Results from Ongoing ARO-RAGE Phase 1/2 Study Demonstrate up to 90% Serum sRAGE Reduction with Mean Maximum Reduction of 80% after Two Doses - Further Data to be [...]

Supported by premier life science industry investors Canaan, OrbiMed, and Hatteras Venture Partners Proceeds to advance AER-01 into the clinic for treatment of chronic obstructive pulmonary disease (COPD); unique targeted [...]

SOUTH SAN FRANCISCO, Calif., March 29, 2023 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies [...]

Asthma is a chronic disease that affects a substantial number of patients worldwide, including children, a number of pharmaceutical companies are involved in developing drugs for asthma. This involvement includes [...]

LEXINGTON, Mass., Feb. 6, 2023 /PRNewswire/ -- https://c212.net/c/link/?t=0&l=en&o=3775499-1&h=1424136920&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D2779419-1%26h%3D2224270520%26u%3Dhttp%253A%252F%252Fwww.pulmatrix.com%252F%26a%3DPulmatrix%252C%2BInc.&a=Pulmatrix%2C+Inc.(NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious disease using its patented iSPERSE(TM) technology, today announced the first [...]

DUBLIN, Jan. 6, 2023 /PRNewswire/ -- The https://www.researchandmarkets.com/reports/5671197/connected-drug-delivery-devices-market-by-type?utm_source=CI&utm_medium=PressRelease&utm_code=g2dm79&utm_campaign=1802541+-+The+Worldwide+Connected+Drug+Delivery+Devices+Industry+is+Expected+to+Reach+%242+Billion+by+2030&utm_exec=jamu273prd report has been added toResearchAndMarkets.com's offering. The global connected drug delivery devices market is envisioned to garner $2,095.2 million by 2030, growing [...]

BEIJING, Dec. 14, 2022 /PRNewswire/ -- Severe asthma, a much more complicated form of asthma, requires treatment with a high dose of steroid-based anti-inflammatory medications (also known as inhaled corticosteroids [...]

Byline: David Wahlberg Aug. 10A Madison doctor who has fought to bring attention to the idea that some cases of asthma might be caused by bacterial infections and can be [...]

Teva Pharmaceuticals, a US affiliate of Teva Pharmaceutical Industries Ltd, announced on 7 Sep 2022 that full results from the CONNECT1 study evaluating the ProAir Digihaler (albuterol sulfate) Inhalation Powder and the Digihaler System in the management of asthma patients compared to standard of care (SoC) albuterol reliever therapy, were published online ahead of print in The Journal of Allergy and Clinical Immunology: In Practice. The study found patients who used the ProAir Digihaler had reductions in weekly average daily short-acting beta agonist (SABA) inhalations and an increase in weekly number of SABA-free days. In addition, patients in the ProAir Digihaler group had a higher number of discussions with physicians around adherence and inhaler technique prompted by the objective data provided by ProAir Digihaler versus patients who used SoC albuterol inhalers. CONNECT1 was a 12-week, multicentre, open-label, randomized, parallel group feasibility study to evaluate the role of the ProAir Digihaler and the Digihaler System in 333 adults and children (aged greater than or equal to 13) with uncontrolled asthma, defined by Asthma Control Test (ACT) score of less than 19. Patients were randomized 1:1 to the ProAir Digihaler or SoC albuterol inhaler. In the ProAir Digihaler group, patients' inhalation data, including inhalation quantity and quality, were monitored once or more per week via a physician-facing dashboard. The study's primary endpoint was clinically meaningful improvement in ACT score, defined as achieving a total ACT score greater than or equal to 20 or an increase of at least three units from baseline at 12 weeks. A Bayesian statistical analysis, adjusted for baseline ACT score and random site effect, was used to understand the effectiveness of the ProAir Digihaler and system with respect to this primary outcome. Participants in the Digihaler System group were trained on the use of the Digital System, including instructions on how to use both the inhaler and smart device app. Patients using the ProAir Digital System (n=167) had a higher probability (85.3%) for clinically meaningful improvements in asthma control versus those using SoC (non-digital) albuterol inhalers (n=166) after three months of treatment. In addition, well-controlled asthma (ACT score of greater than or equal to 20) or an improvement in asthma control (increase in ACT score by greater than or equal to 3 units) was achieved at Week 12 by 92/150 (61%) of participants in the Digihaler group, compared with 89/163 (55%) in the SoC group. More physician-reported interactions due to poor inhaler technique were seen in the Digihaler group compared with the SoC group (52 vs 1, respectively). The Digihaler group also had fewer overall interactions (ie, office visits or telephone calls) that had been planned during a prior visit versus the SoC group (54 vs 104, respectively). Overall, 85 interactions in the patients using the Digihaler System were reported because of data observed due to information observed from the Digihaler System dashboard; of these, 32 (37.6%) interactions were due to increased SABA use. Original source: Teva Pharmaceuticals Industries, website: http://www.tevapharm.com, Copyright Teva Pharmaceuticals Industries Ltd 2022., research and development; Digihaler System; medical devices; ProAir Digihaler; salbutamol sulfate; Teva Pharmaceutical Industries; Teva [...]

Results from Phase III trials conducted by Avillion in over 4,000 patients show that PT027, a novel fixed-dose combination of albuterol and budesonide, significantly reduced the risk of a severe [...]

WAYNE, Pa. and ROCKVILLE, May 18, 2022 (GLOBE NEWSWIRE via COMTEX) -- EQNX::TICKER_START (NASDAQ:AVTX), EQNX::TICKER_END Avalo Therapeutics, Inc. (Nasdaq: AVTX), announced that the first patient has been dosed in the [...]

Full results from the positive MANDALA Phase III trial showed that PT027 (albuterol/budesonide) at two different strengths of budesonide, an inhaled corticosteroid (ICS), used as an as-needed rescue medicine, demonstrated a statistically significant reduction in the risk of a severe exacerbation versus albuterol rescue in patients with moderate to severe asthma. PT027 is a potential first-in-class inhaled, fixed-dose combination rescue medication containing albuterol, a short-acting beta2-agonist (SABA), and budesonide in the US. It is being developed by AstraZeneca and Avillion. Compared with albuterol rescue, PT027 at the 180 mcg albuterol/160 mcg budesonide dose reduced the risk of a severe exacerbation by 27% in adults and adolescents. In the trial, patients were randomized to receive PT027 or albuterol rescue, on top of their usually prescribed maintenance ICS, with or without additional controller medicines. In secondary endpoints, PT027 (180 mcg albuterol/160 mcg budesonide) demonstrated a 33% reduction in mean annualized total systemic corticosteroid exposure and a 24% reduction in annualized severe exacerbation rate. A numerically higher odds of patients experiencing an improvement in symptom control and quality of life was also observed after 24 weeks of treatment with PT027 compared to albuterol rescue. Adverse events (AEs) were similar across the treatment groups in the trial and consistent with the known safety profiles of the individual components, with the most common AEs including nasopharyngitis and headache. In the MANDALA trial, PT027 at a lower budesonide dose (180 mcg albuterol/80 mcg budesonide), also demonstrated a statistically significant reduction of 17% in the risk of severe exacerbation versus albuterol rescue, when used as an as-needed rescue medicine in adults, adolescents, and children aged 4-11 years. The results were published in the New England Journal of Medicine and will be presented at the American Thoracic Society (ATS) 2022 International Conference. Also being presented at the ATS International Conference this week are the positive DENALI Phase III trial results. In this trial, PT027 demonstrated a statistically significant improvement in lung function measured by forced expiratory volume in one second (FEV1), compared to the individual components albuterol and budesonide, and compared to placebo in patients with mild to moderate asthma aged 12 years or older. Onset of action and duration of effect were similar for PT027 and albuterol. The safety and tolerability of PT027 in DENALI was consistent with the known profiles of the components. Original source: AstraZeneca, website: http://www.astrazeneca.com, Copyright AstraZeneca 2022., joint venture; research and development; budesonide; salbutamol; AstraZeneca; [...]

VIENNA, Va., May 2, 2022 /PRNewswire/ -- With more than 24 million Americans living with asthma and 50+ million with allergies, it's vital they have greater access to medical care [...]

BOSTON, April 5, 2022 /PRNewswire/ -- Researchers from Analysis Group, a global leader in health economics and outcomes research (HEOR), and AstraZeneca have published results from their ZEPHYR 1 study, [...]

- Company to Host Pulmonary R&D Day on May 26, 2022 PASADENA, Calif. -- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has filed an application for clearance to [...]

Analyses From NAVIGATOR and PATHWAY Trials Presented at the 2022 AAAAI Annual Meeting THOUSAND OAKS, Calif., Feb. 26, 2022 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced results from a pooled post-hoc [...]

Third Biosimilar to Reach the Market Under Selexis/Generium Commercial License Agreements GENEVA & MOSCOW -- Selexis SA and Generium JSC today announced that Genolar([R]), Generium's biosimilar of omalizumab, is now [...]

Asthma and bronchiectasis patients with chronic rhinosinusitis are associated with increased healthcare utilization according to research from the 2022 AAAAI Annual Meeting. Milwaukee, WI, Feb. 1, 2022 /PRNewswire-PRWeb/ -- Chronic [...]

AUSTIN, Texas, Dec 21, 2021 (GLOBE NEWSWIRE via COMTEX) -- Final Safety and Pharmacokinetic Data Continue to Support Progression to Phase 2 in the Near Term for Treatment of Invasive [...]

REDWOOD CITY, Calif., Nov 30, 2021 (GLOBE NEWSWIRE via COMTEX) -- - Phase 2 Atopic Dermatitis trial of subcutaneous lirentelimab initiated - - Phase 2/3 Chronic Spontaneous Urticaria trial of [...]

AUSTIN, Texas, Nov 08, 2021 (GLOBE NEWSWIRE via COMTEX) -- Initial data from Phase 1b showed Voriconazole Inhalation Powder is Well Tolerated in Asthma Patients Data Supports Progress to Phase [...]

CHICAGO, Oct 07, 2021 (GLOBE NEWSWIRE via COMTEX) -- Scripted (www.scripted.co) announced its new service to transform healthcare into an on-demand approach, where local pharmacists can prescribe and fill medications [...]

Integrating data from the Propeller platform into Dignity Health's EHR improves clinical and operational efficiencies and provides physicians with real-time insights to improve patient treatment decisions SAN FRANCISCO, Oct. 5, [...]

Byline: Aaron Gregg A leading asthma patient group has issued a warning against an unproven coronavirus treatment circulating on social media that is leading some people to post videos of [...]

New York, Sep 17, 2021 (GLOBE NEWSWIRE via COMTEX) -- Reportlinker.com announces the release of the report 'Research Efforts Fuel the Future of Global Obstructive Lung Disease Management' - https://www.reportlinker.com/p06151194/?utm_source=GNW [...]